Related by context. All words. (Click for frequent words.) 67 phase IIa clinical 67 LUMINATE 67 EchoCRT 66 placebo controlled Phase III 66 Phase IIIb 66 multicentre randomized 66 phase IIa 66 pharmacokinetic PK study 65 multicenter clinical 65 clinical pharmacology studies 65 NO# [002] 65 Phase Ib clinical 65 multicenter prospective 65 phase IIIb 65 TG MV 64 RESOLUTE clinical 64 ABSORB trial 64 Phase Ib II 64 Phase #/#a 64 ONTARGET 64 HORIZONS AMI trial 64 Phase Ib study 64 RE LY ® 64 multicenter phase 64 multicentre prospective 64 BRIM3 63 ENDEAVOR clinical 63 Phase 1a clinical 63 double blinded randomized 63 Phase III psoriasis 63 BARI 2D 63 Zenvia Phase III 63 AZILECT ® 63 prospective multicenter 63 preclinical efficacy 63 CLL8 63 IMPROVE HF 63 SUCCEED trial 63 Phase IIIb clinical 63 DAPT Study 62 placebo controlled clinical 62 ENESTnd 62 multicenter multinational 62 GAMMAGARD 62 Acute Decompensated Heart Failure 62 prospective multicentre 62 pivotal bioequivalence 62 Phase IIb III 62 Cardiac Allograft Rejection 62 ToGA 62 StemEx R 62 phase IIb clinical 62 TMC# C# 62 ASPIRE HIGHER 62 HORIZONS AMI 62 SUTENT ® 62 Syllego system 62 Phase III HEAT 62 randomized controlled multicenter 62 prospective observational 62 multicentre 62 Prostate AdenoCarcinoma Treatment 61 lorcaserin Phase 61 Phase III randomized 61 Phase III ADT 61 trastuzumab emtansine T DM1 61 pharmacokinetic PK 61 APEX PD 61 randomized controlled Phase 61 Phase #b/#a 61 PFO migraine 61 CARE HF 61 Phase IIIb study 61 multicenter Phase II 61 ADAGIO study 61 randomized controlled clinical 61 TQT 61 NCIC CTG 61 ENDEAVOR IV 61 randomized Phase III 61 multicenter 61 MelaFind pivotal 61 AIR2 Trial 61 LUX Lung 61 ALSYMPCA 61 prospective multicenter study 61 MERLIN TIMI 61 multicenter randomized controlled 61 SYMMETRY trial 61 Sorafenib HCC Assessment 61 clinical trial 61 ICON7 61 riociguat 61 PROTECT II 60 RE LY 60 multicenter randomized clinical 60 REVEAL Registry 60 COMFORT II 60 placebo controlled randomized 60 PARTNER Trial 60 phase IIb trial 60 Phase IIB 60 randomized multicenter trial 60 CHAMPION PCI 60 APEX AMI trial 60 phase IIb 60 thorough QT 60 RenalGuard System TM 60 ROCKET AF 60 multicenter randomized placebo controlled 60 SPIRIT IV 60 afamelanotide 60 number NCT# ClinicalTrials.gov 60 phase Ib 60 TAXUS ATLAS 60 randomized multicenter 60 CardioFit 60 rALLy trial 60 multicenter randomized Phase 60 Phase 1b trial 60 PROactive Study 60 VITAL Trial 60 Edwards SAPIEN valve 60 Val HeFT 60 Vasogen Celacade 60 prospective multicenter randomized 60 Zemplar Capsules 60 YONDELIS 60 Phase IIa trial 60 CAMMS# 60 AVADO 60 BioMatrix TM 60 ABSORB clinical 60 ADVANCE PD 60 AIM HIGH 60 PLCO 59 prospective randomized multicenter 59 EVEREST II 59 Phase 2a clinical 59 Meta analyzes 59 ExTRACT TIMI 59 EINSTEIN DVT 59 e HEALING 59 EXPLORE Xa 59 trastuzumab DM1 T DM1 59 Phase III 59 NABTT 59 pharmacokinetic pharmacodynamic 59 registrational 59 VALOR trial 59 ALLEGRO 59 sNDA submission 59 Edge STudy 59 fosbretabulin 59 multicenter Phase III 59 Phase III randomized controlled 59 Multicenter 59 SPIRIT FIRST 59 evaluating REVLIMID 59 CURRENT OASIS 7 59 RE LY trial 59 LCP AtorFen 59 multicentre study 59 Randomized controlled 59 Phase 1b clinical 59 PREVU x LT 59 MGCD# clinical trials 59 Phase Ib 59 IIa clinical 59 randomized multicentre 59 clevidipine 59 MYTHOS trial 59 BioSTAR R 59 Phase III ThermoDox 59 confirmatory clinical 59 AIR CF3 59 HPTN 59 BrachySil TM 59 STRIDE PD 59 CLARITY study 59 placebo controlled Phase 59 RE SURGE 59 longitudinal cohort study 59 Phase 2b study 59 PROactive study 59 Trandolapril 59 VTE prevention 59 Resolute DES 59 CUSTOM II 59 BRIM2 59 EURIDIS 59 SYNTAX trial 58 Alvesco R 58 CUSTOM III 58 fully bioabsorbable 58 Randomized Evaluation 58 RE COVER 58 UPLYSO 58 Certican 58 Pharm Olam 58 ExCell study 58 Phase 2b RESTORE CLI 58 GRAVITAS trial 58 TAXUS V 58 Phase IIb clinical 58 SYNTAX 58 TAXUS IV 58 BAL# [002] 58 Quinamed 58 NP2 Enkephalin 58 Safinamide 58 CRLX# 58 Phase 2b kidney transplant 58 REMEDIAL II 58 SWOG 58 Dataflow Manager 58 multicenter study 58 Phase III VISTA 58 Dr. Pingpank 58 prospective nonrandomized 58 EDEMA3 58 RESTORE CLI 58 eprotirome 58 Prospective Randomized 58 AIR CF2 58 biostatistical analysis 58 multicenter trials 58 MIVI TRUST 58 blinded randomized placebo controlled 58 Glybera R 58 viral kinetic 58 CINQUIL 58 IIa trials 58 Pivotal Trial 58 PHX# 58 MIRCERA 58 RIO Lipids 58 TEMSO 58 ENGAGE AF TIMI 58 VESTASYNC 58 dose escalation Phase 58 GetGoal Phase III 58 BLA filing 58 BLA submission 58 Phase IIIB IV 58 Phase 2a preventative 58 Surfaxin LS 58 DASISION 58 novel oral anticoagulant 58 dose escalation clinical 58 ELCAP 58 FDA Investigational Device 58 dirucotide MBP# 58 Phase 2b trial 58 EORTC 58 sunitinib malate 58 randomized Phase 2b 58 ARISE Phase III 58 Phase IIa clinical 58 PRESEPT 58 Dalbavancin 58 cardio renal 58 Phase 2b clinical 58 florbetaben 58 PRoFESS 57 vemurafenib 57 Phase Ib IIa 57 Endeavor drug eluting 57 QTinno TM 57 PROTECT AF 57 Estybon ™ 57 photoprotective drug 57 Acute Ischemic Stroke 57 budesonide MMX Phase III 57 YONDELIS R 57 REALITY Trial 57 Phase 1a 57 observational cohort study 57 randomized blinded placebo 57 Coronary Tree 57 Teplizumab 57 neratinib 57 REMINYL ® 57 BCIRG 57 NICE SUGAR 57 Solorel 57 DIABECELL 57 HCV SPRINT 57 cystinosis patients 57 ORBIT II 57 GEM OS1 57 XIENCE TM 57 MAA submission 57 PRECiSE 57 pain palliation 57 OVATURE 57 arzoxifene 57 Azedra 57 Phase 2a trial 57 LUVENIQ 57 denosumab oncology 57 DF HCC 57 PRESEPT Study 57 prospective observational cohort 57 Evoltra 57 ARDIS 57 SNT MC# 57 Phase Ia 57 ANCHOR trial 57 oral FTY# 57 unblinding 57 BrainGate TM 57 NSABP B 57 prospectively defined 57 COPERNICUS 57 CALGB 57 atherothrombotic disease 57 relapsing multiple sclerosis 57 CIBMTR 57 Current Controlled Trials 57 nonrandomized 57 ICAEL 57 Phase 1b 57 Tracleer R 57 drug eluting stent DES 57 ORMD 57 ASCEND HF 57 CLORETAZINE TM VNP#M 57 Diamyd ® 57 Genz # 57 BOLDER II 57 retrospective observational study 57 Clinicaltrials.gov 57 HDL Selective Delipidation 57 IMA# 57 randomized blinded 57 CURE AF 57 placebo controlled multicenter 57 genomic biomarker 57 ReN# 57 MEND CABG 57 Deforolimus 57 rALLy clinical trial 57 prospective randomized controlled 57 multicenter randomized 57 National Oncologic PET 57 dose escalation phase 57 randomized Phase IIb 57 MADIT CRT 57 multicenter Phase 57 acyclovir Lauriad R 57 AeroLEF TM 57 oral deforolimus 57 ACCORD Lipid 57 Phase lll 57 Medidur TM FA 57 Phase IIA 57 Phase III confirmatory 57 AMPAKINE CX# 57 RRMS patients 57 prelicensure 57 controlled multicenter 57 alvespimycin 57 Medidur FA 57 Valdoxan 57 PROTEGE trial 57 torezolid phosphate 57 Clinical Antipsychotic Trials 57 Dialysis Outcomes 57 Pre RELAX AHF 57 Renal Cell Carcinoma RCC 57 TAXUS Liberte stent 57 clinicaltrials 57 BioZ ICG 57 Phase IIa 57 blinded randomized 57 Dacogen injection 56 ONCONASE R 56 ENDEAVOR III 56 TRANSFORMS 56 RESOLUTE 56 OPTTX 56 AFRS TM 56 PRIMO CABG 56 pharmacodynamic PD 56 PERSEUS 56 HF ACTION 56 CCX# 56 prospective randomized placebo 56 PreCISe 56 fidaxomicin Phase 3 56 observational cohort 56 ACCLAIM II 56 TQT studies 56 Sibutramine Cardiovascular Outcomes 56 Oglemilast 56 ADVATE 56 Phase III multicenter 56 JAK inhibitor 56 ABSORB 56 ASTEROID 56 chemoprevention trials 56 SCD HeFT 56 MADIT II 56 LungSign TM 56 pharmacokinetic pharmacodynamic PK PD 56 recurrent glioma 56 HuMax EGFr 56 RenalGuard TM 56 OMAPRO 56 EGS# 56 trodusquemine 56 Study ADCS 56 PRECISE 56 LibiGel Phase III 56 Vascugel ® 56 OPTIMIZE 56 ataluren 56 phase IIb study 56 TAXUS TM 56 IMPACT IMmunotherapy 56 preclinical pharmacokinetic 56 oncolytic vaccine 56 microplasmin Phase III 56 fidaxomicin Phase 56 IIa clinical trials 56 ongoing Phase IIIb 56 APTIVUS 56 Ovarian Cancer Screening 56 RTOG 56 ENVISION 56 Phase Ib IIa clinical 56 ID NCT# 56 tanespimycin 56 multicenter clinical trials 56 SPIRIT III 56 drug eluting coronary stent 56 ACCLAIM 56 STICH trial 56 dbGaP 56 Diabetic Macular Edema 56 GENASIS trial 56 Medidata Designer 56 NSABP 56 ISEL 56 blinded randomized controlled 56 preclinically 56 Rheos System 56 pivotal Phase III 56 phase III ACCLAIM 56 Plicera 56 confirmatory Phase 3 56 Neuradiab 56 Phase 1b clinical trials 56 Feasibility Trial 56 Urocortin 2 56 USpella 56 STEP BD 56 Carotid Revascularization Endarterectomy vs. 56 Phase #/#a trial 56 Afatinib 56 Zenvia ™ 56 glucokinase activator 56 inhaled AAT 56 oral laquinimod 56 Metricath Gemini 56 relapsed MCL 56 NEVO RES 56 ONTARGET R 56 Elocalcitol 56 MIST II 56 TRITON TIMI 56 Aplidin 56 bepotastine besilate nasal spray 56 Cardiotoxicity 56 ILLUMINATE 56 ticagrelor Brilinta 56 CLIRS 56 radiation dosimetry 56 Asthma Intervention 56 PRE SURGE 56 SIMPADICO 56 INCB# [001] 56 Aryplase 56 Angiolix 56 Phase III Psoriasis 56 Neovasc Reducer 56 Phase 2a 56 Phase 2b clinical trials 56 Relovair 56 label multicenter 56 Vernakalant 56 RE MODEL 56 CRMD# 56 paclitaxel poliglumex 55 Phase IIb 55 Phase 1b dose escalation 55 ATIR ™ 55 LibiGel ® 55 ACOMPLIA R 55 randomized clinical 55 REACH Registry 55 Phase III clinical 55 multicenter randomized double 55 Phase III Clinical Trials 55 CaPSURE 55 bardoxolone 55 trials RCTs 55 LEVADEX ™ 55 BLOOM Behavioral modification 55 ENDEAVOR II 55 Bayer HealthCare Onyx Pharmaceuticals 55 NCCTG 55 TAXUS ARRIVE 55 ToxCast 55 phase Ib clinical 55 Endeavor DES 55 Telatinib 55 Max Neeman 55 Yondelis ® 55 CAPHOSOL 55 PROSTVAC TM 55 non nucleoside 55 EMPHASIS HF 55 phase IIb III 55 PD2i ® 55 Betaferon ® 55 Aplidin R 55 Fabry Disease 55 ColorectAlert TM 55 enroller 55 Mipomersen 55 teriflunomide 55 confirmatory Phase III 55 Candesartan 55 ImmuKnow assay 55 IL# PE#QQR 55 Phase Forward InForm 55 confirmatory pivotal 55 GISSI HF 55 bioequivalency 55 ALTROPANE 55 Alzhemed TM 55 eliglustat tartrate 55 vidofludimus 55 PROMUS Element Stent 55 Raptiva R 55 Phase IIb trials 55 CATIE AD 55 recurrent GBM 55 ACRIN 55 pharmacoeconomic analysis 55 icatibant 55 viral kinetics 55 XIENCE V Everolimus Eluting 55 FOLOTYN ® 55 postapproval 55 MGuard ™ 55 immatics 55 depsipeptide 55 prospective longitudinal 55 Randomised 55 PEARL SC 55 INTERCEPT platelets 55 STEDESA 55 zotarolimus eluting stent 55 Firazyr 55 TAXUS VI 55 masked placebo controlled 55 GCP compliant 55 Allovectin 7 ® 55 TAXUS Liberte Stent 55 Trofex 55 atherothrombosis 55 PREOS 55 IMPACT DCM 55 p# biomarker 55 OvaRex R 55 ZYBRESTAT fosbretabulin 55 crizotinib PF # 55 AIR CF1 55 ADMIRE HF 55 ularitide 55 carotid artery stenting 55 brivaracetam 55 AZILECT R 55 ADVEXIN therapy 55 Plenaxis TM 55 Carfilzomib 55 controlled multicenter Phase 55 vernakalant hydrochloride 55 GATTEX ™ 55 Phase IIb trial 55 MEND CABG II 55 Peptidomics 55 BioNumerik 55 microarray gene expression 55 Multi MERCI 55 blind randomized placebo 55 Delcath PHP System 55 Xanafide 55 myoblast therapy 55 kinase profiling 55 Stenting Trial CREST 55 Intervention Effectiveness 55 prospective randomized 55 longitudinal cohort 55 Dr. Kandzari 55 ALTTO 55 eCRF 55 VESTAsync 55 ACCORD Eye 55 Phase #b/#a clinical 55 pharmacokinetics PK 55 Long Lesion 55 ospemifene 55 CHAMPION PLATFORM 55 EOquin TM 55 Angiox R 55 DNA methylation markers 55 Calci CLEAR 55 CHARISMA trial 55 axitinib 55 Diamyd r vaccine 55 NV1FGF 55 PREOS R 55 Diamyd R 55 PROTEGE 55 AVERROES 55 EMPHASIS HF trial 55 OvaRex ® MAb 55 Pirfenidone 55 farletuzumab 55 multicentre randomized controlled 55 Ambrisentan 55 pharmacokinetic PK profile 55 dirucotide 55 Microplasmin 55 Catena ® 55 Oral NKTR 55 Icatibant 55 synthetic retinoid 55 QTinno 55 JAK2 inhibitor 55 HQK 55 BiovaxID Phase 55 multicenter randomized Phase III 55 omacetaxine mepesuccinate 55 proteomic biomarkers 55 CEQ# 55 secondary efficacy endpoints 55 MoxDuo IR 55 Ridaforolimus 55 VADT 55 PPMI 55 Patient Registry 54 Phase IIB clinical 54 Nasdaq IDRA today 54 PD2i CA 54 Silodosin 54 double blinded placebo 54 XIENCE V Stent System 54 Phase #/#a clinical 54 MAQC 54 CLIRS trial 54 Multiple Ascending Dose 54 Aethlon Hemopurifier R 54 OmniWave 54 BRILINTA 54 TOLAMBA 54 AERx iDMS 54 Elagolix 54 NDA resubmission 54 Hepatocellular Carcinoma HCC 54 CBLC# 54 Phase III Clinical Trial 54 PROACT 54 PREDICTIVE 54 BOLDER 54 Daclizumab 54 patientswith 54 EDEMA4 54 Q#IR 54 varespladib 54 Pyridorin 54 ASSERT 54 Virtual Histology 54 chronic myocardial ischemia 54 PICSO ® 54 mg/m2 cohort 54 COPAXONE R 54 Registry NOPR 54 landmark ATHENA 54 Phase IIa trials 54 SCENESSE ® 54 NSABP C 54 Acute Myocardial Infarction 54 Raptiva ® 54 Thorough QT 54 OMNARIS HFA 54 elotuzumab 54 briakinumab 54 Amrubicin 54 Squalamine 54 everolimus eluting stent 54 Anavex #-# 54 TACI Ig 54 PROMUS TM 54 dose escalation trial 54 subanalysis 54 Endeavor Resolute DES 54 Phase IIb clinical trials 54 ProUroScan 54 European Sepsis Trial 54 CANCIDAS 54 tolerability pharmacokinetics 54 CVac 54 randomized discontinuation 54 rALLy 54 ImmuKnow R 54 Nasdaq ONXX today 54 randomized placebo controlled 54 TBC# 54 Schizophrenia Treatment 54 ThermoDox ® clinical 54 PRECISE trial 54 Biobanks 54 XIENCE 54 lumiliximab 54 Referenced EEG ® 54 Orazol 54 tramiprosate ALZHEMED TM 54 Dermscan 54 ARCOXIA 54 MADIT CRT trial 54 Phase III pivotal 54 Exploratory IND 54 retrospective observational 54 Loramyc R 54 canakinumab 54 Lomitapide 54 placebo controlled 54 Ovarian PLCO Cancer 54 Thorough QT TQT 54 TAXUS Liberté stent 54 HGS# 54 ProLindac TM 54 Primary endpoints 54 Octreolin 54 Lu AA# 54 Manja Bouman CEO 54 pharmacokinetic characteristics 54 randomized controlled clinical trials 54 clinical trials 54 everolimus eluting stents 54 deforolimus 54 EQUIP OB 54 Left Ventricular Dysfunction 54 ERSPC 54 Diabetic Macular Edema DME 54 anti arrhythmic drug 54 Phlexglobal 54 ganaxolone 54 PROMUS R 54 Proxinium TM 54 PRIMO CABG2 54 ongoing Phase 1b 54 NADiA ProsVue 54 RIGScan CR 54 relapsed MM 54 TEC #OL 54 APTIMA HPV 54 Phase 2b 54 CAPACITY trials 54 Onbrez Breezhaler 54 Pafuramidine 54 ascending dose 54 Eluting Coronary Stent System 54 multicentric 54 StemEx 54 ADHERE 54 Diabetes Risk Score 54 phase 2a 54 RoACTEMRA 54 HuMax CD4 54 Tarvacin TM 54 DIABECELL ® 54 IRESSA 54 ACTIVE W 54 PrevOnco 54 NTx TM -# 54 Drug Eluting Stent System 54 registrational trial 54 Tryton Side Branch 54 Investigator Initiated 54 CTSAs 54 BR.# 54 iPrEx 54 TEMODAL 54 Phase III TRIST 54 Oral Insulin Capsule 54 Hyphanox 54 APEX AMI 54 Multicenter Automatic Defibrillator Implantation 54 myopic CNV 54 Coronary Revascularization 54 Phase III randomized placebo 54 Solorel TM 54 randomized controlled trial 54 Rilonacept 54 Delcath Phase III 54 BACcel 54 Vantia Therapeutics 54 Tanespimycin 54 MiDAS 54 Augment Injectable 54 CIMZIA ™ 54 Scopus Affiliation Identifier 54 psychometrically sound 54 Complications Trial 54 Neurostep TM 54 candidate CRLX# 54 Liprostin 54 REG1 54 Pagoclone 54 immunotherapeutic vaccine 54 randomized double 54 NN# [001] 54 BST CarGel R 54 ENMD # 54 LipiScan 54 relapsing remitting MS RRMS 54 HuMax CD#b 54 IMC #B 54 Cloretazine 54 OncoGel 54 Decompensated Heart Failure 54 randomized crossover 54 Hepatocellular Carcinoma 54 ATIR TM 54 Multicenter Phase 54 STENT 54 Omapro 54 Phase 2b monotherapy 54 MAGE A3 ASCI 54 evaluating tivozanib 54 International Verapamil SR 54 PharmaVigilant 54 Pharmacokinetic 54 ICAAC IDSA 54 RESIST studies 53 Risk Stratification 53 ProImmune 53 Pimavanserin 53 delipidation 53 FlutiformTM 53 Harry Palmin President 53 vitro ADME 53 Outpatient Setting 53 recombinant factor VIIa 53 PD2i CA Cardiac Analyzer 53 Alfimeprase 53 Tolvaptan 53 PrevOnco ™ 53 Motesanib 53 adult chronic ITP 53 Screening Trial 53 Dermylex TM 53 AVOREN 53 PreCISe study 53 Randomized Clinical Trial 53 Refractory Angina 53 PREVENT IV 53 Aethlon Hemopurifier ® 53 multicentre randomized double 53 Proellex TM 53 tramiprosate Alzhemed TM 53 VentriPoint Diagnostic System 53 TMC# [002] 53 Angiox ® 53 lomitapide 53 COSIRA trial 53 IASLC 53 prognostic variables 53 WTCCC 53 efficacy endpoint 53 BNC# 53 ROTATEQ 53 Intervention Trial GAIT 53 ORAL Sync 53 ActivityBase 53 eSubmissions 53 Rezular 53 combination REOLYSIN 53 putative biomarkers 53 gene expression assays 53 NCT# ClinicalTrials.gov 53 randomized controlled 53 velafermin 53 PhotoCure 53 transcatheter aortic valve implantation 53 ABCSG 53 DermaVir Patch 53 Blinatumomab 53 Hedgehog antagonist 53 specified secondary endpoints 53 tolevamer 53 FACTIVE tablets 53 PHASE III 53 Pazopanib 53 Phase III clinical trials 53 MGN# 53 DU #b 53 evaluating Actimmune 53 ITAX 53 placebo controlled clinical trials 53 Multimodality 53 Denufosol 53 tezampanel NGX# 53 multicenter placebo controlled 53 desvenlafaxine 53 Ranolazine 53 Recurrent Fracture Trial 53 Medifacts 53 Drug Eluting Stents 53 Multaq R 53 OpenClinica Enterprise 53 APPRAISE 53 ruboxistaurin 53 forodesine 53 TPI ASM8 53 ritonavir boosted danoprevir 53 Cardio3KG 53 THALOMID 53 FREEDOMS 53 efficacy tolerability 53 Aurora kinase inhibitors 53 Medidur ™ FA 53 null responder HCV 53 Numoda 53 Aurexis 53 Firazyr ® 53 PREVU * 53 BRITE 53 Epanova 53 TM Drug Eluting 53 human microdosing 53 treatment naive genotype 53 GALNS 53 PEGylated interferon 53 clinical 53 UK Biobank 53 microRNA profiling 53 acute coronary syndromes ACS 53 lorvotuzumab mertansine 53 eTag assays 53 NEVO TM 53 Ocrelizumab 53 SCH # 53 Interventional Cardiologists 53 unblind 53 ELONVA 53 HeFT 53 retrospective cohort 53 NeuroFlo 53 FibroScan ® 53 tonabersat 53 blinded placebo controlled 53 ICH GCP 53 torcetrapib atorvastatin 53 Teysuno 53 Dapagliflozin 53 dalbavancin 53 ELACYT 53 CR# vcMMAE 53 Prostate Lung Colorectal 53 olanzapine LAI 53 orBec 53 OHR/AVR# 53 ISTH 53 OvaDx 53 Neuradiab TM 53 azilsartan medoxomil 53 LITHE 53 Traficet EN 53 RHUCIN 53 sipuleucel T 53 dosing cohort 53 MetaVision Suite 53 BioDisc 53 ALN TTR 53 CYPHER R Sirolimus eluting 53 Patient Outcomes 53 oral ridaforolimus 53 registrational trials 53 bazedoxifene conjugated estrogens 53 REVIVE TA 53 HuLuc# 53 aclidinium bromide